Author: Rajanish Giri; Taniya Bhardwaj; Meenakshi Shegane; Bhuvaneshwari R. Gehi; Prateek Kumar; Kundlik Gadhave
Title: Dark Proteome of Newly Emerged SARS-CoV-2 in Comparison with Human and Bat Coronaviruses Document date: 2020_3_14
ID: n7ylgqfu_55
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.13.990598 doi: bioRxiv preprint intrinsic disorder content of 9.28%, comparatively lower than that of the Human SARS ORF9b protein. MoRFs lies in the N-terminal region of ORF9b proteins ( Table 2, Supplementary Table 7 and 8). In the absence of other viral proteins, its first 41 residues have been demonstrated to induce membranous struct.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.13.990598 doi: bioRxiv preprint intrinsic disorder content of 9.28%, comparatively lower than that of the Human SARS ORF9b protein. MoRFs lies in the N-terminal region of ORF9b proteins ( Table 2, Supplementary Table 7 and 8). In the absence of other viral proteins, its first 41 residues have been demonstrated to induce membranous structures similar to DMVs [106] . The available crystal structure also has the missing electron density in the N-terminal region suggests that these flexible amino acids are likely to interact with host lipids. The first 3-29 residues of SARS-CoV2 are identified as disorder-based protein binding region that may have role in its interaction with host lipids and formation of DMVs. Supplementary Tables 9, 10, and 11 represents nucleotide-binding residues for ORF9b of SARS-CoV-2, Human SARS, and Bat CoV.
Search related documents:
Co phrase search for related documents- amino acid and bind region: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- amino acid and crystal structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- amino acid and disorder content: 1
- amino acid and electron density: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- amino acid and flexible amino acid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- amino acid and host lipid: 1, 2, 3, 4, 5, 6, 7
- amino acid and intrinsic disorder content: 1
- amino acid and membranous structure: 1
- amino acid and supplementary table: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
- amino acid and viral protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77
- available crystal structure and crystal structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- available crystal structure and viral protein: 1
- bind region and crystal structure: 1
- bind region and flexible amino acid: 1
- bind region and nucleotide bind: 1
- bind region and viral protein: 1, 2, 3, 4, 5, 6, 7, 8, 9
- crystal structure and electron density: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- crystal structure and supplementary table: 1, 2
- crystal structure and viral protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69
Co phrase search for related documents, hyperlinks ordered by date